Pancreatic Endocrine Tumor– Pipeline Review, 2019

Table of Content:

1. Introduction

1.1. Report Overview

2. Pancreatic Endocrine Tumor- Overview

3. Executive Summary

4. Pancreatic Endocrine Tumor: Pipeline Assessment

4.1. By Stage of Development

4.2. By Route of Administration

4.3. By Drug Class

4.4. By Molecule Type

4.5. By Therapy Area / Indication

4.6. By Drug Target

4.7. By Sponsor

5. Pancreatic Endocrine Tumor: Company & Drug Profiles

5.1. Clinical Stage

5.1.1. CVM-1118– TaiRx, Inc.

5.1.1.1. Company Overview

5.1.1.2. Product Description

5.1.1.3. R&D Status & Development Activities

5.1.1.4. Mechanism of Action

5.1.1.5. Molecule Type

5.1.1.6. Stage of Development

5.1.1.7. Indications

5.1.1.8. Route of Administration

5.1.1.9. Funding

5.1.2. MVT-5873 – MabVax Therapeutics Holdings, Inc.

5.1.2.1. Company Overview

5.1.2.2. Product Description

5.1.2.3. R&D Status & Development Activities

5.1.2.4. Mechanism of Action

5.1.2.5. Molecule Type

5.1.2.6. Stage of Development

5.1.2.7. Indications

5.1.2.8. Route of Administration

5.1.2.9. Funding

5.1.3. RX-3117– Rexahn Pharmaceuticals, Inc.

5.1.3.1. Company Overview

5.1.3.2. Product Description

5.1.3.3. R&D Status & Development Activities

5.1.3.4. Mechanism of Action

5.1.3.5. Molecule Type

5.1.3.6. Stage of Development

5.1.3.7. Indications

5.1.3.8. Route of Administration

5.1.3.9. Funding

5.1.4. Others

5.2. Preclinical

5.2.1. Company Overview

5.2.2. Product Description

5.2.3. R&D Status & Development Activities

5.2.4. Mechanism of Action

5.2.5. Molecule Type

5.2.6. Indications

5.2.7. Route of Administration

5.2.8. Funding

6. Pancreatic Endocrine Tumor: An Overview on Dormant & DiscontinuedPipeline Candidates

6.1. Overview

6.2. Product Description

6.3. Reason for Discontinuation

7. Pancreatic Endocrine Tumor: Additional Key Insights

7.1. Epidemiology Overview:Pancreatic Endocrine Tumor

7.2. Current Market Scenario:Pancreatic Endocrine Tumor Therapeutics

8. Pancreatic Endocrine Tumor: News, Press Releases and Conference Details

Note:

1) This Table of Content is tentative and subject to change as the research progresses.

2) Please note that the drug candidates included as examples were in the pipeline when this TOC was designed and their status might have changed since then.